Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials |
| |
| Authors: | Meredith M. Regan Olivia Pagani Gini F. Fleming Barbara A. Walley Karen N. Price Manuela Rabaglio Rudolf Maibach Barbara Ruepp Alan S. Coates Aron Goldhirsch Marco Colleoni Richard D. Gelber Prudence A. Francis |
| |
| Affiliation: | 1. International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA;2. Harvard Medical School, Boston, MA, USA;3. International Breast Cancer Study Group, Bern, Switzerland;4. Institute of Oncology of Southern Switzerland (IOSI), Ospedale Italiano, Viganello, Lugano, Switzerland and Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland;5. Alliance for Clinical Trials in Oncology and University of Chicago Hospitals, Chicago, IL, USA;6. National Cancer Institute of Canada Clinical Trial Group and Tom Baker Cancer Centre, Calgary, Alberta, Canada;7. Frontier Science and Technology Research Foundation, Boston, MA, USA;8. International Breast Cancer Study Group Coordinating Center, Bern, Switzerland;9. Inselspital, Bern, Switzerland;10. University of Sydney, Sydney, Australia;11. European Institute of Oncology, Milan, Italy;12. Harvard School of Public Health, Boston, MA, USA;13. Peter MacCallum Cancer Centre, St Vincent''s Hospital, and University of Melbourne, Australia;14. Australia and New Zealand Breast Cancer Trials Group (ANZBCTG), Newcastle, Australia |
| |
| Abstract: | ObjectivesIn 2003 the International Breast Cancer Study Group (IBCSG) initiated the TEXT and SOFT randomized phase III trials to answer two questions concerning adjuvant treatment for premenopausal women with endocrine-responsive early breast cancer: 1-What is the role of aromatase inhibitors (AI) for women treated with ovarian function suppression (OFS)? 2-What is the role of OFS for women who remain premenopausal and are treated with tamoxifen?MethodsTEXT randomized patients to receive exemestane or tamoxifen with OFS. SOFT randomized patients to receive exemestane with OFS, tamoxifen with OFS, or tamoxifen alone. Treatment was for 5 years from randomization.ResultsTEXT and SOFT successfully met their enrollment goals in 2011. The 5738 enrolled women had lower-risk disease and lower observed disease-free survival (DFS) event rates than anticipated. Consequently, 7 and 13 additional years of follow-up for TEXT and SOFT, respectively, were required to reach the targeted DFS events (median follow-up about 10.5 and 15 years). To provide timely answers, protocol amendments in 2011 specified analyses based on chronological time and median follow-up. To assess the AI question, exemestane + OFS versus tamoxifen + OFS, a combined analysis of TEXT and SOFT became the primary analysis (n = 4717). The OFS question became the primary analysis from SOFT, assessing the unique comparison of tamoxifen + OFS versus tamoxifen alone (n = 2045). The first reports are anticipated in mid- and late-2014.ConclusionsWe present the original designs of TEXT and SOFT and adaptations to ensure timely answers to two questions concerning optimal adjuvant endocrine treatment for premenopausal women with endocrine-responsive breast cancer.Trial RegistrationTEXT: Clinicaltrials.gov NCT00066703SOFT: Clinicaltrials.gov NCT00066690 |
| |
| Keywords: | Premenopausal Endocrine-responsive Early breast cancer Adjuvant therapy Trial design |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
